Karyopharm Therapeutics, Inc. (KPTI)
0.5175
-0.03
(-5.24%)
USD |
NASDAQ |
Oct 23, 16:00
0.5075
-0.01
(-1.93%)
After-Hours: 20:00
Karyopharm Therapeutics Enterprise Value : 202.82M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 202.82M |
| October 22, 2026 | 203.47M |
| October 21, 2026 | 200.71M |
| October 20, 2026 | 199.22M |
| October 19, 2026 | 198.93M |
| October 16, 2026 | 199.93M |
| October 15, 2026 | 199.04M |
| October 14, 2026 | 198.23M |
| October 13, 2026 | 200.78M |
| October 12, 2026 | 202.54M |
| October 09, 2026 | 204.81M |
| October 08, 2026 | 204.70M |
| October 07, 2026 | 205.72M |
| October 06, 2026 | 205.83M |
| October 05, 2026 | 206.29M |
| October 02, 2026 | 209.28M |
| October 01, 2026 | 210.75M |
| September 30, 2026 | 218.76M |
| September 29, 2026 | 218.42M |
| September 28, 2026 | 227.83M |
| September 25, 2026 | 227.83M |
| September 24, 2026 | 230.32M |
| September 23, 2026 | 230.78M |
| September 22, 2026 | 232.37M |
| September 21, 2026 | 233.27M |
| Date | Value |
|---|---|
| September 18, 2026 | 233.73M |
| September 17, 2026 | 231.68M |
| September 16, 2026 | 229.64M |
| September 15, 2026 | 226.01M |
| September 14, 2026 | 227.38M |
| September 11, 2026 | 227.60M |
| September 10, 2026 | 227.83M |
| September 09, 2026 | 229.42M |
| September 08, 2026 | 230.10M |
| September 04, 2026 | 231.68M |
| September 03, 2026 | 231.23M |
| September 02, 2026 | 231.68M |
| September 01, 2026 | 233.05M |
| August 31, 2026 | 237.81M |
| August 28, 2026 | 233.50M |
| August 27, 2026 | 235.09M |
| August 26, 2026 | 235.54M |
| August 25, 2026 | 234.63M |
| August 24, 2026 | 233.27M |
| August 21, 2026 | 235.54M |
| August 20, 2026 | 232.37M |
| August 19, 2026 | 236.45M |
| August 18, 2026 | 234.86M |
| August 17, 2026 | 232.14M |
| August 14, 2026 | 236.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals, Inc. | 9.537B |
| Relay Therapeutics, Inc. | 3.093B |
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -67.02M |
| Revenue (Quarterly) | 33.43M |
| Total Expenses (Quarterly) | 100.46M |
| EPS Diluted (Quarterly) | -2.316 |
| Gross Profit Margin (Quarterly) | 96.75% |
| Profit Margin (Quarterly) | -200.5% |
| Earnings Yield | -2.53K% |
| Normalized Earnings Yield | -2056.68 |